Physician profile
Christopher Scola
NPI 1386625432
$20,441.65
in general payments reported to CMS, 2019-2025
44 companies · $5,867 in 2025
The $5,867 reported for 2025 was more than what 87% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,455 · 2020: $335 · 2021: $2,040 · 2022: $2,430 · 2023: $2,880 · 2024: $5,435 · 2025: $5,867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,002.26 |
| Education | $179.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,953.71 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $2,160.04 | 2019-2025 | Enbrel, Tavneos, Evenity |
| Janssen Biotech, INC. | $1,931.12 | 2019-2025 | Tremfya, Simponi Aria |
| Ucb, INC. | $1,547.08 | 2019-2025 | Bimzelx, Cimzia |
| Astrazeneca Pharmaceuticals LP | $1,005.53 | 2021-2025 | Saphnelo |
| Mallinckrodt Hospital Products INC. | $952.13 | 2021-2025 | Acthar |
| Pfizer INC. | $830.65 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $718.45 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $703.21 | 2019-2025 | Orencia |
| Lilly USA, LLC | $623.18 | 2019-2025 | Taltz, Zepbound |
| Glaxosmithkline, LLC. | $540.13 | 2019-2025 | Benlysta |
| Genentech USA, INC. | $509.85 | 2019-2025 | Actemra, Rituxan, Gazyva |
| Ani Pharmaceuticals, INC. | $427.92 | 2023-2025 | Purified Cortrophin Gel |
| Aurinia Pharma U.S., INC. | $298.40 | 2021-2025 | Lupkynis |
| Fresenius Kabi USA, LLC | $287.95 | 2023-2025 | Idacio |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $287.09 | 2019-2025 | Ultomiris, Strensiq |
| Genzyme Corporation | $244.96 | 2024-2025 | |
| Actelion Pharmaceuticals US, INC. | $235.86 | 2024-2025 | Opsumit, Opsynvi, Uptravi |
| Sandoz INC. | $232.61 | 2023-2025 | Hyrimoz, Jubbonti |
| Horizon Therapeutics Plc | $227.68 | 2021-2023 | Krystexxa |
| Octapharma USA, INC. | $226.30 | 2021-2025 | Octagam Immune Globulin (Human), Panzyga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $217.00 | 2023-2025 | Ofev, Cyltezo |
| Kiniksa Pharmaceuticals International, Plc | $175.77 | 2024 | Arcalyst |
| Sobi, INC | $151.97 | 2021-2025 | |
| Kiniksa Pharmaceuticals, LTD. | $127.51 | 2021-2023 | Arcalyst |
| Abbott Laboratories | $124.99 | 2022 | |
| Organon LLC | $119.10 | 2021-2025 | Hadlima, Renflexis |
| Scilex Pharmaceuticals INC. | $108.39 | 2024-2025 | |
| Kyowa Kirin, INC. | $75.21 | 2023-2024 | Crysvita |
| Merck Sharp & Dohme LLC | $46.69 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $44.48 | 2025 | Simlandi |
| Almatica Pharma LLC | $42.65 | 2025 | Teriparatide |
| Fidia Pharma USA INC. | $37.80 | 2019-2020 | |
| Depuy Synthes Sales INC. | $28.22 | 2023 | Monovisc |
| Bioventus LLC | $28.10 | 2021 | |
| Medexus Pharma, INC. | $27.65 | 2019 | |
| Endo USA, INC. | $25.57 | 2025 | Xiaflex |
| Ultragenyx Pharmaceutical INC. | $24.49 | 2022 | |
| Alvogen INC | $18.61 | 2025 | Teriparatide |
| Tersera Therapeutics LLC | $16.78 | 2025 | Quzyttir |
| Hikma Pharmaceuticals USA | $15.72 | 2022 | |
| Gilead Sciences, INC. | $15.08 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $14.15 | 2020 | |
| Pacira Therapeutics, INC. | $11.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Scola listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.